

Yves Fradet

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10383999/yves-fradet-publications-by-citations.pdf>

Version: 2023-03-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

6,307
citations

32
h-index

55
g-index

55
ext. papers

7,640
ext. citations

7.9
avg, IF

4.92
L-index

#	Paper	IF	Citations
54	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1015-1026	57.2	1784
53	PCA3: a molecular urine assay for predicting prostate biopsy outcome. <i>Journal of Urology</i> , 2008 , 179, 1587-92	1.5	345
52	PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. <i>Urology</i> , 2007 , 69, 532-5	1.5	347
51	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	47.5	322
50	Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005 , 66, 35-63	1.5	318
49	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. <i>Science Translational Medicine</i> , 2011 , 3, 94ra72	16.9	282
48	Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. <i>European Urology</i> , 2013 , 64, 846-54	9.9	262
47	A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. <i>Journal of Urology</i> , 2007 , 178, 68-73; discussion 73	1.5	224
46	A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. <i>Journal of Urology</i> , 2007 , 178, 62-7	1.5	212
45	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019 , 176, 831-843.e23	34.5	210
44	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , 2014 , 66, 815-25	9.9	184
43	Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2010 , 184, 1907-13	1.5	181
42	Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005 , 66, 64-74	1.5	142
41	Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. <i>European Urology</i> , 2009 , 56, 659-67	9.9	141
40	uPM3, a new molecular urine test for the detection of prostate cancer. <i>Urology</i> , 2004 , 64, 311-5; discussion 315-6	1.5	138
39	Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. <i>Journal of Urology</i> , 2012 , 188, 58-62	1.5	126
38	Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. <i>Urologia Internationalis</i> , 2015 , 94, 1-24	1.8	118

37	Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. <i>European Urology</i> , 2013 , 63, 201-9	9.9	97
36	A Prostate Cancer "Nimbusus": Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017 , 72, 665-674	9.9	98
35	Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. <i>Canadian Journal of Urology</i> , 1997 , 4, 400-405	0.8	81
34	Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. <i>European Urology</i> , 2014 , 66, 913-9	9.9	73
33	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1579-1587	2.1	69
32	Diagnostic Accuracy of Urinary Cytology, and Deoxyribonucleic Acid Flow Cytometry and Cytology on Bladder Washings During Followup for Bladder Tumors. <i>Journal of Urology</i> , 1997 , 157, 1660-1664	1.5	63
31	Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. <i>Modern Pathology</i> , 2007 , 20, 1121-7	9.4	53
30	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 931-945	20.9	51
29	Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. <i>Journal of Urology</i> , 1999 , 162, 2024-8	1.5	48
28	DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. <i>Journal of Urology</i> , 1999 , 161, 1189-1191	1.5	45
27	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , 2015 , 68, 570-7	9.9	41
26	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 31.e17-24	2.7	39
25	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016 , 10, E46-80	1.2	40
24	Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. <i>Current Opinion in Urology</i> , 2009 , 19, 243-6	2.7	37
23	COMPARISON OF MOLECULAR AND CONVENTIONAL STRATEGIES FOR FOLLOWUP OF SUPERFICIAL BLADDER CANCER USING DECISION ANALYSIS. <i>Journal of Urology</i> , 2000 , 163, 752-757	1.5	31
22	The burden of prostate cancer in Canada. <i>Canadian Urological Association Journal</i> , 2009 , 3, S92-S100	1.2	26
21	Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. <i>Clinical Cancer Research</i> , 2014 , 20, 2971-83	12.3	25
20	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019 , 25, 1615-1626	49.3	23

19	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 441-8	2.7	23
18	Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. <i>Diagnostic Pathology</i> , 2015 , 10, 67	2.9	18
17	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 328-334	2.7	16
16	Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 300.e9-300.e15	2.7	10
15	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. <i>Cancer Prevention Research</i> , 2016 , 9, 189-95	3.1	7
14	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e1122-e1128	3.2	7
13	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018 , 12, E281-E297	1.2	6
12	A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 701-706	3.6	5
11	Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer. <i>Canadian Urological Association Journal</i> , 2012 , 6, 396-8	1.2	2
10	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , 2022 ,	12.3	1
9	Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-68. <i>European Urology</i> , 2010 , 57, e2-e3	9.9	
8	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018 , 4, S1-S43	0.9	
7	Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES. <i>Canadian Family Physician</i> , 2007 , 53, 1140-3	0.8	
6	The treatment of prostate cancer: how is failure defined and how can it be minimized?. <i>Canadian Journal of Urology</i> , 1997 , 4, 39-43	0.8	
5	Building a Canadian Translational Bladder Cancer Research Network. <i>Canadian Urological Association Journal</i> , 2020 , 14, E475-E481	1.2	
4	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 117-117	2.1	
3	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 96-96	2.1	
2	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 49-49	2.1	

- 1 Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5051-5051 2.1